Associate Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Oncology
Dr. Jeffrey A. Engelman, MD
|
|
Give Review
Jeffrey A. Engelman, MD is an expert in the field of Oncology. He went to medical school at Albert Einstein College of Medicine of Yeshiva University. He received 1 awards: "Elected Member". Doctor Jeffrey A. Engelman, MD has written publications. He has 103 publications published with PubMed. The lastest paper is: 'Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.' He accepts all Medicare patients.
Publications
- Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer.
- Assessment of ABT-263 activity across a Cancer cell line collection leads to a potent combination therapy for small-cell lung Cancer.
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
- Combined MEK and PI3K inhibition in a mouse model of pancreatic Cancer.
- Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer.
- Anchored multiplex PCR for targeted next-generation sequencing.
- Patient-derived models of acquired resistance can identify effective drug combinations for Cancer.
- The Double Life of p85.
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib.
- Cancer Progress Report 2014.
- Genotyping Lung Cancer Is an Investment in the Future.
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors.
- Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS mutant lung Cancers.
- Ceritinib in ALK-rearranged non-small-cell lung Cancer.
- ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics.
- Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance.
- Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors.
- The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung Cancer.
- PI3K regulates MEK/ERK signaling in Breast cancer via the Rac-GEF, P-Rex1.
- mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1.
- Tyrosine kinase gene rearrangements in epithelial Malignancies.
- Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2.
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer.
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma.
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer.
- Acquired resistance to crizotinib from a mutation in CD74-ROS1.
- Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer.
- Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition.
- ALK in Lung Cancer: Past, Present, and Future.
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models.
- FGFR1 Amplification in Squamous Cell Carcinoma of The Lung.
- Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified Breast cancer brain metastases.
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung Cancer: updated results from a phase 1 study.
- Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung Cancer.
- Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET.
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors.
- Genetic changes in squamous cell lung Cancer: a review.
- A murine lung Cancer co-clinical trial identifies genetic modifiers of therapeutic response.
- SnapShot: Non-Small Cell Lung Cancer.
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal Cancers to RAF inhibition with vemurafenib.
- Activation of PI3K signaling in Merkel cell carcinoma.
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers.
- EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung Cancers.
- Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
- Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Sma...
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal Cancers.
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab.
- BIM expression in treatment-naive Cancers predicts responsiveness to kinase inhibitors.
- Using Tandem Mass Spectrometry in Targeted Mode to Identify Activators of Class IA PI3K in Cancer.
- A New BATTLE in the Evolving War on Cancer.
- STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung Cancers harboring the fusion oncogene EML4-ALK.
- Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers.
- Genotypic and histological evolution of lung Cancers acquiring resistance to EGFR inhibitors.
- Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid Tumors.
- Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
- Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung Cancer.
- Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung Cancer.
- EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung Cancer.
- Anaplastic lymphoma kinase inhibition in non-small-cell lung Cancer.
- Chemoprevention meets glucose control.
- PIKing the right patient.
- Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenoCarcinoma of the cecum.
- Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic Lung tumors.
- Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human Cancer.
- An ErbB3 antibody, MM-121, is active in Cancers with ligand-dependent activation.
- Differences underlying EGFR and HER2 oncogene addiction.
- The PI3K pathway as drug target in human Cancer.
- Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
- Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung Cancer.
- BRAF gene amplification can promote acquired resistance to MEK inhibitors in Cancer cells harboring the BRAF V600E mutation.
- Differential induction of apoptosis in HER2 and EGFR addicted Cancers following PI3K inhibition.
- Toward noninvasive genomic screening of lung Cancer patients.
- PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon Cancer.
- Overcoming resistance to tyrosine kinase inhibitors: lessons learned from Cancer cells treated with EGFR antagonists.
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung Cancers.
- Modeling oncogene addiction using RNA interference.
- EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung Cancer.
- Acquired resistance to EGFR tyrosine kinase inhibitors in Cancer cells is mediated by loss of IGF-binding proteins.
- Summary statement novel agents in the treatment of lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
- First-line gefitinib in patients with advanced non-small-cell lung Cancer harboring somatic EGFR mutations.
- Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung Cancer.
- A sweet new role for EGFR in Cancer.
- PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung Cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
- Human Breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB...
- The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung Cancer.
- Biochemistry. PI3K charges ahead.
- Bronchial and peripheral murine Lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
- MET amplification leads to gefitinib resistance in lung Cancer by activating ERBB3 signaling.
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung Cancer.
- The role of the ErbB family members in non-small cell lung Cancers sensitive to epidermal growth factor receptor kinase inhibitors.
- Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
- Differential effects of gefitinib and cetuximab on non-small-cell lung Cancers bearing epidermal growth factor receptor mutations.
- The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.
- Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to gelda...
- Factors predicting response to EGFR tyrosine kinase inhibitors.
- Epidermal growth factor receptor mutations in non-small-cell lung Cancer: implications for treatment and tumor biology.
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung Cancer cell lines.
- Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.
- Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
Schools
Albert Einstein College of Medicine of Yeshiva University
Brigham and Women39s Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Anemia
- Breast Cancer
- ENT Cancer
- Liver Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- GHI PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
Massachusetts General Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538159108 |
| Last Name Of The Provider | ENGELMAN |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
|
Dr. Rebecca S. Heist, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paiman P. Ghoroghchian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Hassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas R. Spitzer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer S. Temel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ken S. Zaner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreea M. Negroiu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel Buchsbaum, MD
This Doctor is OpenDoctor Recommended.
|